Subject: FW: SOF/VEL
From: Tamar Gabunia </O=EXCHORGANIZATION/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=E6CA04F38EC94D0CADAB9CBDF90FCDDE-TAMAR G>
To: info </o=ExchOrganization/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2069f7f4886b493dbd84f07150d67a52-info>
Date: Mon, 13 Jan 2020 13:21:31 +0000

გთხოვთ დაარეგისტრიროთ!

From: Ben Kamarck [mailto:[email-masked]]
Sent: 13 January, 2020 17:18
To: Tamar Gabunia <[email-masked]>; Ekaterine Adamia <[email-masked]>
Cc: Graeme Robertson <[email-masked]>
Subject: RE: SOF/VEL

Dear Dr. Gabunia,

In relation to our commitment to supply sofosbuvir/velpatasvir to the Georgian Ministry of Labour, Health and Social Affairs for its national HCV elimination campaign, Gilead requests the granting of an import permit for 4,003 bottles of MyHEP ALL registered by Mylan in India.

The bottles come from lots 3105355 and 3105979, manufactured in September 2019 with expiration in August 2021.  Please see attached certificates of analysis and patient leaflets.  Registration with DCGI in India will come separately.

The product will ship in January 2020.

Best regards,

Ben Kamarck

Senior Director, Gilead Global Patient Solutions